title: Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers.
abstract: OBJECTIVE
  To study evolvement in pharmacotherapy of atrial fibrillation from 1995 to 2004.
  
  
  RESULTS
  All Danish patients were discharged following first-time atrial fibrillation and their pharmacotherapy was identified by individual-level-linkage of nationwide registers of hospitalization and drug dispensing from pharmacies. A total of 108 791 patients survived 30 days after discharge and were included. In 1995-1996, 7.4% of the patients received beta-blockers, increasing to 44.3% in 2003-2004. The corresponding figures for amiodarone were 2.9 and 5.4%. In contrast, use of nondihydropyridine calcium-channel blockers, digoxin, sotalol, and class 1C antiarrhythmics decreased from 20.6, 63.9, 21.3, and 4.0% in 1995-1996 to 12.6, 43.8, 4.2, and 1.3% in 2003-2004, respectively. Notably, patients receiving anticoagulants increased from 29.8 to 43.5%. Multivariate logistic regression analysis revealed females to be associated with more use of digoxin, but less use of amiodarone and oral anticoagulants than males. Patients above 80 years received less pharmacotherapy, apart from digoxin treatment that was more commonly used in elderly.
  
  
  CONCLUSIONS
  Pharmacotherapy of atrial fibrillation has changed towards increased beta-blocker use with a coincident decrease in the use of other rate-limiting drugs and sotalol. Treatment with amiodarone or class 1C antiarrhythmics remained very low. Oral anticoagulant therapy increased considerably, but women and elderly were apparently undertreated.
authors.affiliation: Department of Cardiology, Bispebjerg University Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark. mlh@heart.dk
authors.forename: Morten Lock
authors.initials: ML
authors.lastname: Hansen
authors.forename: Niels
authors.initials: N
authors.lastname: Gadsbøll
authors.forename: Gunnar H
authors.initials: GH
authors.lastname: Gislason
authors.forename: Steen Z
authors.initials: SZ
authors.lastname: Abildstrom
authors.forename: Tina K
authors.initials: TK
authors.lastname: Schramm
authors.forename: Fredrik
authors.initials: F
authors.lastname: Folke
authors.forename: Jens
authors.initials: J
authors.lastname: Friberg
authors.forename: Rikke
authors.initials: R
authors.lastname: Sørensen
authors.forename: Søren
authors.initials: S
authors.lastname: Rasmussen
authors.forename: Henrik E
authors.initials: HE
authors.lastname: Poulsen
authors.forename: Lars
authors.initials: L
authors.lastname: Køber
authors.forename: Mette
authors.initials: M
authors.lastname: Madsen
authors.forename: Christian
authors.initials: C
authors.lastname: Torp-Pedersen
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003718:Denmark; D004077:Digoxin / Q000627:therapeutic use; D004358:Drug Therapy / Q000639:trends*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010351:Patient Discharge; D012042:Registries; D012189:Retrospective Studies; D013015:Sotalol / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D004077:Digoxin; D013015:Sotalol; D000638:Amiodarone